Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children

NCT00383123
View directory record Official record
Conditions
Influenza
Interventions
Fluarix™, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,327 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
40
States / cities
Antioch, California • Fairfield, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Centralized Reminder Recall - Flu RCT2

NCT03294473
View directory record Official record
Conditions
Influenza, Human, Orthomyxoviridae Infections, RNA Virus Infections, Virus Disease, Respiratory Tract Infections, Respiratory Tract Disease, Vaccines, Physiological Effects of Drugs
Interventions
R/R - Autodialers, R/R - Texting, R/R - mailed postcard
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months to 17 Years
Enrollment
70,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 22, 2026, 6:21 PM EDT
Recruiting No phase listed Observational

Respiratory Virus Sampling and Repository

NCT05266222
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 6:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

NCT00133536
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 9 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 6:21 PM EDT
Completed No phase listed Observational

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

NCT05787444
View directory record Official record
Conditions
SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
Interventions
LumiraDx SARS-CoV-2 & Flu A/B
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
2 Years and older
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cullman, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

PRO#0118: Decitabine Plus Mini Flu-Bu

NCT01455506
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine plus Fludarabine and Busulfan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

NCT00389532
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

NCT01766921
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
1,393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Hollywood, Florida • Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACTIVATE in Public Housing

NCT06075732
View directory record Official record
Conditions
Pneumonia, Influenza, Varicella Zoster, Meningitis, COVID-19, Vaccine Hesitancy
Interventions
Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

NCT06124638
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Panbio™ COVID-19/Flu A&B Panel
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
2 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Pelham, Alabama • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of LAIV4 in Children With Asthma

NCT03600428
View directory record Official record
Conditions
Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
Interventions
Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV)
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945
View directory record Official record
Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
Swine Influenza
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 92 Years
Enrollment
627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
11
States / cities
Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 22, 2026, 6:21 PM EDT
Terminated Phase 4 Interventional Results available

The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics

NCT03686514
View directory record Official record
Conditions
Influenza
Interventions
FLUARIX QUADRIVALENT
Biological
Lead sponsor
Emory University
Other
Eligibility
42 Years to 71 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 22, 2026, 6:21 PM EDT
Completed No phase listed Observational

Idylla IFV-RSV Panel Clinical Testing

NCT02786381
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
Not listed
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 22, 2026, 6:21 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

NCT03734237
View directory record Official record
Conditions
Influenza, Influenza-like Illness, Influenza Vaccines
Interventions
Egg based influenza vaccines, Recombinant influenza vaccines, Cell-culture based influenza vaccines
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
15,448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
9
States / cities
San Diego, California • Annapolis, Maryland • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019
View directory record Official record
Conditions
Influenza
Interventions
Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years to 40 Years
Enrollment
753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

NCT01205581
View directory record Official record
Conditions
HIV, Cancer
Interventions
Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 6:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Elderberry for Immune Support

NCT05435144
View directory record Official record
Conditions
Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness, Cold
Interventions
Elderberry, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 22, 2026, 6:21 PM EDT
Terminated Phase 1 Interventional Results available

A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza

NCT01053663
View directory record Official record
Conditions
Influenza
Interventions
Tamiflu
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 365 Days
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

A Study of a Live Intranasal Influenza Vaccine in Children With Cancer

NCT00906750
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Inactivated influenza vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

NCT00111579
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 36 Months
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Layton, Utah • Ogden, Utah • Pleasant Grove, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 22, 2026, 6:21 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Opioid, HIV and Immune System

NCT04304768
View directory record Official record
Conditions
Immune Defect
Interventions
Fluzone Quadrivalent
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 6:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

NCT03748524
View directory record Official record
Conditions
Immunity, Cellular
Interventions
Influenza Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 22, 2026, 6:21 PM EDT